Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTcH phase 2 trial of trametinib + hydroxychloroquine in metastatic refractory pancreatic cancer
2021-006276-16Phase 2Active
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and hydroxychloroquine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Cancer Trials Ireland. Primary endpoint: 12-week progression-free survival. Started Jan 2022; status: active.
02
Drugs
trametinibhydroxychloroquine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2021-006276-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006276-16.